Go to Page # Page of 15

Radionuclides for treatment of painful bone metastasis

 Lars J. Petersen, MD DMSc CBA
Description: Palliative strategy, bone mets, NCCN Recommendation, Interaction with bisphosphonates, Radionuclide with chemotherapy, Hematological toxicity
Views: 1980
Domain: Medical
Category: Biotech/Pharma
Radionuclides for treatment of painful bone metastasis

Lars J. Petersen, MD DMSc CBA
Department of Clinical Physiology, Viborg Hospital & Clinical Institute, University of Aarhus

Incidence of bone mets
Cancer type Incidence in advanced disease (%) Median Survival (mo) 5-Year survival (%) Osteoblastic bone mets (%)

Myeloma Breast Prostate Lung Kidney Thyroid

95-100 65-75 65-95 30-40 20-25 60

... See more

Recent Presentations

Impact of Clinician Burnout on Patient Safety

Main objective is to identify strategies for improving well-being & resilience in the healthcare workforce. Explain, clinician burnout is a patient care & healthcare workforce prob

Paul Abramowitz
27 June, 2019

Innovation in Allergy Immunotherapy

ASIT biotech treatments consist of a mixture of purified peptides from different selected sizes, produced from natural sources of allergens for allergy immunotherapy.

26 June, 2019
Bionure Farma
25 June, 2019